Department of Cardiovascular Diseases, Mayo Clinic Arizona, Scottsdale, Arizona.
Department of Medicine, Division of Cardiology, University of California Medical Center, San Francisco, California.
JACC Heart Fail. 2019 Apr;7(4):281-290. doi: 10.1016/j.jchf.2018.11.004. Epub 2019 Feb 6.
This study tested the hypothesis that the extent of left ventricular (LV) eccentric structural remodeling in heart failure with reduced ejection fraction (HFrEF) is directly associated with clinical event responses to cardiac resynchronization therapy (CRT).
Whether the severity of LV structural remodeling influences CRT treatment effects is unknown.
COMPANION (Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure) trial data were analyzed retrospectively. Left ventricular internal dimensions at end diastole indexed by body surface area (LVEDDI) were measured pre-randomization by 2-dimensional echocardiography. LVEDDI values were stratified around the median value of 35 mm/m, and CRT (including CRT-P [CRT with only pacing capability] and/or CRT-D [CRT with an implantable defibrillator]) treatment effects were assessed and compared by LVEDDI group. Patients assigned to these treatments were compared to those undergoing optimal pharmacologic therapy (OPT) for the outcomes of all-cause mortality (ACM) or ACM and heart-failure hospitalization (ACM/HFH).
In the LVEDDI ≥35 mm/m group (n = 614), CRT vs. OPT was associated with a lower ACM/HFH hazard ratio (HR) (HR: 0.53; 95% confidence interval [CI]: 0.40 to 0.70; p <0.001), whereas in the LVEDDI <35 mm/m group, the CRT vs. OPT ACM/HFH hazard ratio was not statistically significant (HR: 0.80; 95% CI: 0.59 to 1.08; p = 0.15). For ACM alone, in the LVEDDI ≥35 mm/m group, the hazard ratio for CRT-P was 0.59 (95% CI: 0.39 to 0.90; p = 0.012) and for CRT-D 0.50 (95% CI: 0.32 to 0.77; p = 0.002). Neither of the CRT groups showed a statistically significant reduction in ACM in the LVEDDI <35 mm/m group.
Larger versus smaller LVEDDIs are associated with a reduction in ACM with CRT-P or CRT-D treatment, and with a more effective reduction in ACM/HFH for the combined CRT treatment groups.
本研究旨在验证左心室(LV)偏心结构重构程度与射血分数降低的心力衰竭(HFrEF)患者对心脏再同步治疗(CRT)临床反应之间存在直接相关性的假设。
LV 结构重构的严重程度是否影响 CRT 治疗效果尚不清楚。
回顾性分析 COMPANION(心力衰竭药物治疗、起搏和除颤比较)试验数据。通过二维超声心动图在随机分组前测量左心室舒张末期内径指数(LVEDDI)。根据 35mm/m 的中位数将 LVEDDI 值分层,并根据 LVEDDI 组评估和比较 CRT(包括仅起搏能力的 CRT-P [CRT-P] 和/或带有植入式除颤器的 CRT-D [CRT-D])治疗效果。将接受这些治疗的患者与接受最佳药物治疗(OPT)的患者进行比较,以评估全因死亡率(ACM)或 ACM 和心力衰竭住院(ACM/HFH)的结局。
在 LVEDDI≥35mm/m 组(n=614)中,与 OPT 相比,CRT 治疗与较低的 ACM/HFH 风险比(HR)相关(HR:0.53;95%置信区间[CI]:0.40 至 0.70;p<0.001),而在 LVEDDI<35mm/m 组中,CRT 与 OPT 的 ACM/HFH HR 无统计学意义(HR:0.80;95%CI:0.59 至 1.08;p=0.15)。对于单纯 ACM,在 LVEDDI≥35mm/m 组中,CRT-P 的 HR 为 0.59(95%CI:0.39 至 0.90;p=0.012),CRT-D 的 HR 为 0.50(95%CI:0.32 至 0.77;p=0.002)。在 LVEDDI<35mm/m 组中,两个 CRT 组均未显示出 ACM 统计学意义的降低。
与 LVEDDI 较小的患者相比,LVEDDI 较大的患者接受 CRT-P 或 CRT-D 治疗后,ACM 降低,且 CRT 联合治疗组的 ACM/HFH 降低更有效。